Wall Street expects a year-over-year increase in earnings on higher revenues when Quest Diagnostics (DGX) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on October 22, 2024, might help the stock move higher if these key numbers are bette ...

First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or through Quest's consumer-initiated test platform at questhealth.com SECAUCUS, N.J., Oct. 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnosti ...

The medical laboratory testing industry is growing at a 1-3% compound annual growth rate and is dominated by two publicly traded companies. Quest Diagnostics (NYSE: DGX ) is the stronger of the two companies and is actively I am an individual investor with over two decades of investing experience. I am passionate about finding great value buys and pursuing dividend growth investing, from domestic to international companies. I invest in businesses, not stocks!I cover all aspects of value investing, dividend ...

Quest Diagnostics (DGX) is set to release its third-quarter 2024 results on Oct. 22, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share (EPS) of $2.35 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.73%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.31%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. DGX's Q3 Estimates For the third quarter of ...

Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J., Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system. Financial terms of the transaction were not disclosed. The goal of the transaction is to broaden access to c ...

Quest Diagnostics Inc. (DGX) continues the strong momentum in its expanding portfolio of Advanced Services, which is poised to help it grow in the upcoming quarters. The company strategically deploys AI and automation to improve its operational quality and efficiency, while Invigorate aims to reach its annual target. Its base business volume remains robust, which is highly encouraging. However, the mounting debt burden on its balance sheet and industry headwinds could pose challenges for Quest Diagnostics' ...

SECAUCUS, N.J., Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode ...

Quest Diagnostics (DGX) has been gaining from its existing solid customer relationships, new customer wins, broad health plan access and advanced diagnostics offerings. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving DGX Stock Quest Diagnostics has been experiencing robust volume growth in its core business (excluding COVID testing), banking on the growth of new physician and hospital customers, a more favorable test mix with increased use of advanced diagnostics, continued strength in he ...

Quest Diagnostics (DGX) and Sentara Health Plans announced a multi-year strategic collaboration to expand access to high-quality, affordable and comprehensive laboratory testing for the members of Sentara Health Plans. Per the deal, starting Jan. 1, 2025, DGX will be the exclusive independent national laboratory provider of clinical laboratory and anatomic pathology services for Sentara Health Plans' members, including commercial and government programs. The agreement applies to Sentara Health Plans' member ...

Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va., Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Sentara Health Plans, the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system, today announced a multiyear strategic collaboration designed to expand access to high-quality, affordable and comprehe ...